The Playbook 100

CELG @ $57.68 (Celgene) develops therapies to treat cancer and immune-inflammatory related diseases. Revenues have increased between 43% and 76% during each of the last four quarters. Earnings have increased between 72% and 136% during the same time frame and are expected to grow 43% this year and another 50% in 2009 to $2.28 a share. We've made money a few times in this company over the last few years and feel a good risk to reward is being offered by establishing a position here with a tight stop at $53. Our option players have a nice option listed below.

IPO's and New Issues

V @ $56.50 (Visa) gapped higher, so we didn't chase it. We will wait for a pull back toward the $45 level for now and until then, feel Mastercard (MA) offers us a better value.

ETF's

FXI @ $123.69 (Ishares Xinhua China) is an exchange traded fund seeking performance corresponding to the FTSE/Xinhua China 25 Index. We will establish a position on continued weakness that allows us an entry at $115 and will place a tight stop at $110.

Options

VCS AF @ $29.90 (Celgene January 2009 $30 Calls) are only costing us $2.22 in time value and could be a huge winner on a Celgene breakout above $60. Otherwise, we risk $4 to the downside for potentially $20 plus to the upside.

This newsletter has been sent to you for informative purposes only and in no event should be construed as a representation by The Stock Playbook or its employees as an offer to sell or solicitation of an offer to buy any securities. The factual information given is taken from sources we believe to be reliable, but is not guaranteed as to its accuracy or completeness. The opinions expressed should be given only such weight as opinions warrant.  employees and/or family members may have a position in the securities mentioned and may make purchase and/or sales of such securities from time to time in the open market or otherwise Recipients of The Stock Playbook prohibited from, directly or indirectly, distributing, forwarding , plagiarizing or copying any part of this message without expressed written consent from The Stock Playbook. Some content may have been based, at least in part, on material gathered from Investor's Business Daily ® and/or YAHOO!®